AlphaLISA versus ELISA-based detection of interleukin 18 in healthy subjects and patients with end-stage renal disease

References

• Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol 2003;73:213–24.
   PubMed Web of Science ®Google Scholar
• Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008;223:20–38.
   PubMed Web of Science ®Google Scholar
• Gangemi S, Mallamace A, Minciullo PL, Santoro D, Merendino RA, Savica V, Bellinghieri G. Involvement of interleukin-18 in patients on maintenance haemodialysis. Am J Nephrol 2002;22:417–21.
   PubMed Web of Science ®Google Scholar
• Lonnemann G, Novick D, Rubinstein M, Dinarello CA. Interleukin-18, interleukin-18 binding protein and impaired production of interferon-gamma in chronic renal failure. Clin Nephrol 2003;60:327–34.
   PubMed Web of Science ®Google Scholar
• Chiang CK, Hsu SP, Pai MF, Peng YS, Ho TI, Liu SH, Hung KY, Tsai TJ, Hsieh BS. Plasma interleukin-18 levels in chronic renal failure and continuous ambulatory peritoneal dialysis. Blood Purif 2005;23:144–8.
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Novick D, Rubinstein M, Lonnemann G. Interleukin 18 and interleukin 18 binding protein: possible role in immunosuppression of chronic renal failure. Blood Purif 2003;21:258–70.
   PubMed Web of Science ®Google Scholar
• Uchimura T, Motomiya Y, Okamura H, Hashiguchi T, Miura M, Uji Y, Iwamoto H, Maruyama I. Marked increases in macrophage colony-stimulating factor and interleukin-18 in maintenance hemodialysis patients: comparative study of advanced glycation end products, carboxymethyllysine and pentosidine. Nephron 2002;90:401–7.
   Google Scholar
• Girndt M, Sester U, Kaul H, Köhler H. Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. J Am Soc Nephrol 1998;9:1689–96.
   PubMedGoogle Scholar
• Yano A, Nakao K, Sarai A, Akagi S, Kihara T, Morimoto H, Nakamura A, Hiramatsu M, Nagake Y, Makino H. Elevated serum interleukin-18 levels might reflect the high risk of hospitalization in patients on peritoneal dialysis. Nephrology (Carlton) 2005;10:576–82.
   Google Scholar
• Chiang CK, Hsu SP, Pai MF, Peng YS, Ho TI, Liu SH, Hung KY, Tsai TJ. Interleukin-18 is a strong predictor of hospitalization in haemodialysis patients. Nephrol Dial Transplant 2004;19:2810–5.
   PubMedGoogle Scholar
• Parikh CR, Jani A, Melnikov VY, Faubel S, Edelstein CL. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Diseases 2004;43:405–14.
   PubMed Web of Science ®Google Scholar
• Parikh CR, Coca SG, Thiessen-Philbrook H, Shlipak MG, Koyner JL, Wang Z, Edelstein CL, Devarajan P, Patel UD, Zappitelli M, Krawczeski CD, Passik CS, Swaminathan M, Garg AX, Consortium ftT-A. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol 2011;22:1748–57.
   PubMed Web of Science ®Google Scholar
• Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney International 2008;73: 1008–16.
   PubMed Web of Science ®Google Scholar
• Hall IE, Yarlagadda SG, Coca SG, Wang Z, Doshi M, Devarajan P, Han WK, Marcus RJ, Parikh CR. IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J Am Soc Nephrol 2010;21:189–97.
   PubMed Web of Science ®Google Scholar
• Nicoletti F, Di Marco R, Mangano K, Patti F, Reggio E, Nicoletti A, Bendtzen K, Reggio A. Increased serum levels of interleukin-18 in patients with multiple sclerosis. Neurology 2001;57:342–4.
   Google Scholar
• Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, Kennedy K, Carter R, Wei XQ, Xu D, Field M, Foulis A, Liew FY, McInnes IB. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999;104: 1393–401.
   PubMed Web of Science ®Google Scholar
• Hultgren O, Andersson B, Hahn-Zoric M, Almroth G. Serum concentration of interleukin-18 is up-regulated in patients with ANCA-associated vasculitis. Autoimmunity 2007;40:529–31.
   PubMed Web of Science ®Google Scholar
• Kanai T, Watanabe M, Okazawa A, Nakamaru K, Okamoto M, Naganuma M, Ishii H, Ikeda M, Kurimoto M, Hibi T. Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohn's disease. Gastroenterology 2000;119:1514–23.
   PubMed Web of Science ®Google Scholar
• Flisiak I, Klepacki A, Chodynicka B. Plasma and scales levels of interleukin 18 in comparison with other possible clinical and laboratory biomarkers of psoriasis activity. Biomarkers 2006;11:194–200.
   PubMed Web of Science ®Google Scholar
• Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, Tedgui A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001;104:1598–603.
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002;106:24–30.
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Luc G, Ducimetière P, Arveiler D, Ferrières J, Amouyel P, Evans A, Cambien F, Tiret L, Group PS. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003;108: 2453–9.
   PubMed Web of Science ®Google Scholar
• Eglen RM, Reisine T, Roby P, Rouleau N, Illy C, Bossé R, Bielefeld M. The use of AlphaScreen technology in HTS: current status. Curr Chem Genomics 2008;1:2–10.
   PubMedGoogle Scholar
• Taniguchi M, Nagaoka K, Kunikata T, Kayano T, Yamauchi H, Nakamura S, Ikeda M, Orita K, Kurimoto M. Characterization of anti-human interleukin-18 (IL-18)/interferon-gamma-inducing factor (IGIF) monoclonal antibodies and their application in the measurement of human IL-18 by ELISA. J Immunol Methods 1997;206:107–13.
   PubMed Web of Science ®Google Scholar
• Note for guidance. The European Agency for the Evaluation of Medicinal Products. February 2003. (http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002662.pdf)
   Google Scholar
• Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–10.
   PubMed Web of Science ®Google Scholar
• Ullman EF, Kirakossian H, Singh S, Wu ZP, Irvin BR, Pease JS, Switchenko AC, Irvine JD, Dafforn A, Skold CN. Luminescent oxygen channeling immunoassay: measurement of particle binding kinetics by chemiluminescence. Proc Natl Acad Sci USA 1994;91:5426–30.
   PubMed Web of Science ®Google Scholar
• Ullman EF, Kirakossian H, Switchenko AC, Ishkanian J, Ericson M, Wartchow CA, Pirio M, Pease J, Irvin BR, Singh S, Singh R, Patel R, Dafforn A, Davalian D, Skold C, Kurn N, Wagner DB. Luminescent oxygen channeling assay (LOCI): sensitive, broadly applicable homogeneous immunoassay method. Clin Chem 1996;42: 1518–26.
   PubMed Web of Science ®Google Scholar
• Guidance for industry; Bioanalytical Method Validation; FDA/CDER/CVM; May 2001 (http://www.fda.gov).
   Google Scholar
• Bolstad N, Warren DJ, Bjerner J, Kravdal G, Schwettmann L, Olsen KH, Rustad P, Nustad K. Heterophilic antibody interference in commercial immunoassays; a screening study using paired native and pre-blocked sera. Clin Chem Lab Med 2011;49:2001–6.
   PubMed Web of Science ®Google Scholar
• Boscato LM, Stuart MC. Incidence and specificity of interference in two-site immunoassays. Clin Chem 1986;32: 1491–5.
   PubMed Web of Science ®Google Scholar
• Poulsen F, Jensen KB. A luminescent oxygen channeling immunoassay for the determination of insulin in human plasma. J Biomol Screen 2007;12:240–7.
   PubMed Web of Science ®Google Scholar
• Chiang CK, Huang JW, Hsu SP, Ho TI, Pai MF, Peng YS, Liu SH, Hung KY, Tsai TJ. Plasma interleukin-18 levels in hemodialysis patients: increased by dialysis process and association with interleukin-6 and tumor necrotic factor-alpha. Blood Purif 2006;24:174–9.
   PubMedGoogle Scholar